- Home
- NAGE vs GUG Comparison
NAGE vs GUG Comparison
Compare NAGE & GUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NAGE | GUG |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.6M | 518.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NAGE | GUG |
|---|---|---|
| Price | $5.08 | $15.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 992.1K | 76.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $20.75 | N/A |
| Revenue Next Year | $19.96 | N/A |
| P/E Ratio | $21.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.73 | $13.90 |
| 52 Week High | $14.66 | $16.50 |
Technical Indicators
Market Signals| Indicator | NAGE | GUG |
|---|---|---|
| Relative Strength Index (RSI) | 41.32 | 42.44 |
| Support Level | $4.74 | $15.46 |
| Resistance Level | $5.32 | $15.97 |
| Average True Range (ATR) | 0.29 | 0.21 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 29.38 | 0.00 |
Price Performance
Historical ComparisonAbout NAGE Niagen Bioscience Inc.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
About GUG Guggenheim Active Allocation Fund of Beneficial Interest
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.